Companies > Johnson & Johnson
by Jeffrey Benzing | August 7th, 2012

Agreement on the fine and disgorgement had reportedly been reached in November.

by Jeffrey Benzing | August 1st, 2012

The new chairman of the Tokyo-based medical device maker — already rocked by a billion dollar accounting scandal — now says the company also may have violated the Foreign Corrupt Practices Act in Brazil.

by Main Justice Editors | July 25th, 2012

SUBSCRIBERS: Please click here to see the full list of articles published by Just Anti-Corruption from July 16 to 20, 2012. Includes articles that did not appear on the home page.

by Mary Jacoby | July 17th, 2012

SUBSCRIBERS: Please click here for the latest articles. UPDATED with new articles at 2:02 p.m. and 3:30 p.m. EDT.

by Jeffrey Benzing | July 17th, 2012

Final approval will come after a September hearing.

by Main Justice Editors | July 16th, 2012

SUBSCRIBERS: Please click here to see the full list of articles published by Just Anti-Corruption from July 9 to 13, 2012. Includes articles that did not appear on the home page.

by Jeffrey Benzing | July 13th, 2012

The company has agreed to compliance changes and $10 million in attorney’s fees.

by Main Justice Editors | July 13th, 2012

Subscribers: Please click on this link to access articles published on July 12. Please check this link for updates during the day. UPDATED with new stories at 1:54 p.m. and 4:10 p.m. EDT.

by Reuters | June 21st, 2012
by Jeffrey Benzing | June 20th, 2012

Greece must speed up prosecutions and streamline foreign bribery laws, an OECD report says.

by Jeffrey Benzing | May 25th, 2012

Numerous shareholder derivative suits are pending related to FCPA investigations as investors look for damages and payment for attorneys’ fees. Recent settlements haven’t paid big prizes.

by Jeffrey Benzing | May 24th, 2012

Up in New Jersey, Johnson & Johnson faces both state and federal shareholder derivative lawsuits related to Foreign Corrupt Practices Act investigation by the Justice Department.
In April 2011, Johnson & Johnson entered into a deferred prosecution agreement with the Justice Department for FCPA charges against subsidiary DePuy Inc. Concurrently, the company settled a civil complaint [...]

by Rachel G. Jackson | May 22nd, 2012

Reps. Elijah Cummings (D-Md.) and Henry Waxman (D-Calif.) pressed for answers on potential conflicts of interest between the Chamber of Commerce’s push to amend U.S. foreign bribery laws and corporate representatives on its board. UPDATE: 4:14 p.m.

by Rachel G. Jackson | April 26th, 2012

The investigation of Bristol-Myers, part of a larger probe of the pharmaceutical industry, began in 2006.

by Mary Jacoby | April 20th, 2012

Edward Garnier laid out a timetable for deferred prosecution agreement legislation in Britain in an interview with Just Anti-Corruption.

by Main Justice staff | April 9th, 2012
by Rachel G. Jackson | March 26th, 2012

The company settled charges that it had violated U.S. foreign bribery law in connection with an ongoing sweep of the medical device industry. UPDATED 5:13 p.m. with additional comment from Biomet.

by Mary Jacoby | March 22nd, 2012

Judges in Great Britain have been skeptical of such agreements, viewing them as a usurpation of the judiciary’s sentencing powers.

by | November 27th, 2011

Otherwise, any legislation may not make it to Parliament before 2014.

by Mary Jacoby | November 20th, 2011

The industry-wide corruption probe, announced in a 2009 speech by DOJ Criminal Division chief Lanny Breuer, stemmed from internal investigations by Pfizer and rival Johnson & Johnson.

by Christopher M. Matthews | November 16th, 2011

The Justice Department and the Securities and Exchange Commission have been examining since 2004 whether the company violated the Foreign Corrupt Practices Act.

by Christopher M. Matthews | November 8th, 2011

The company has previously disclosed that the SEC and DOJ are investigating it for potential violations of the FCPA.

by Aruna Viswanatha | August 12th, 2011

Some 20 Foreign Corrupt Practices Act settlements from the last year are already eligible to produce a bounty.

by Channing Turner | June 16th, 2011

After cultivating a reputation for his public service efforts, Tony Herman gets picked up by the FEC.

by Aruna Viswanatha | June 13th, 2011

The tobacco company, which paid around $20 million last year to settle a foreign bribery case, hired Gibson, Dunn & Crutcher as its three-year compliance monitor.

by Aruna Viswanatha | May 25th, 2011

The SEC approved new rules, following a high-pitched lobbying campaign by business interests.

by Aruna Viswanatha | May 5th, 2011

The company said the SEC sought information about the company’s business in the Asia-Pacific region.

by Christopher M. Matthews | May 2nd, 2011

How Johnson & Johnson saved $17 million.

by Aruna Viswanatha | April 29th, 2011

Lilly said on Friday it is in “advanced discussions” with the SEC to resolve a long-running investigation into the company’s business in Poland and other countries.

by Christopher M. Matthews | April 29th, 2011

The DOJ’s Criminal Fraud Section and the SEC are investigating at least five other major pharmaceutical companies: GlaxoSmithKline PLC; Baxter International Inc.; Eli Lilly & Co.; Bristol-Myers Squibb Co.; and Merck & Co.

READING THE TEA LEAVES ON COMPLIANCE CREDIT: Jodi Avergun, partner at Cadwalader, Wickersham & Taft LLP, discusses recent cases that may signal what the Justice Department is willing to define as effective compliance.

Mary B. Jacoby

Mary Jacoby is the founder of Main Justice and Editor-in-Chief of Just Anti-Corruption.

Ernst & Young's FIDS Practices

Dealing with complex issues of fraud, regulatory compliance and business disputes can detract from efforts to achi...more